Natalie Holles, Astellas

Astel­las fol­lows up $3B gene ther­a­py buy­out with $109M plan to ac­cel­er­ate a man­u­fac­tur­ing boom

Just weeks af­ter clos­ing on their $3 bil­lion Au­dentes buy­out, Astel­las is fol­low­ing up with a $109 mil­lion plan to build a new man­u­fac­tur­ing fa­cil­i­ty in or­der to be­come a play­er in the boom­ing gene ther­a­py field.

Astel­las is build­ing out a 135,000-square-foot plant from the ground up, with plans to add 200 jobs in San­ford, NC, a re­gion that has be­come home to a thriv­ing hub of drug-mak­ing op­er­a­tions. Like a num­ber of star­tups in the field, Au­dentes has been pur­su­ing AAV pro­grams fash­ioned with tech orig­i­nal­ly de­signed by Penn’s Jim Wil­son.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.